Clinical Trial

A Wearable Sensor Platform for Remote Monitoring of Individuals on the Frontotemporal Dementia Spectrum

Study acronym: ReMoTe
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The primary objective of this clinical study is to provide the initial validation for monitoring biomarkers of symptoms and functioning for individuals with frontotemporal lobar degeneration (FTLD) syndromes. Researchers at BioSensics, Johns Hopkins University School of Medicine, and Massachusetts General Hospital will use wearable sensors, computerized speech, psychomotor, and cognitive assessments to create outcome measures and digital biomarkers for FTLD syndromes. Researchers will deploy this digital health solution to monitor 60 patients with FTLD syndromes for 24 months with study visits every 6 months.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-29.
Trial Details
NCT Number NCT07569367
Lead Sponsor BioSensics
Collaborators: Johns Hopkins University, Massachusetts General Hospital, United States Department of Defense
Conditions Frontotemporal Lobar Degeneration (FTLD), Frontotemporal Dementia (FTD), Corticobasal Degeneration, Corticobasal Syndrome (CBS)
Enrollment 60 participants
Start Date 2026-08-01
Primary Completion 2030-08-15 (estimated)
Study Completion 2030-12-15 (estimated)
Updated on ClinicalTrials.gov 2026-05-08